Read by QxMD icon Read

md anderson

Nitin Chakravarti, Doina Ivan, Van A Trinh, Isabella C Glitza, Jonathan L Curry, Carlos Torres-Cabala, Michael T Tetzlaff, Roland L Bassett, Victor G Prieto, Wen-Jen Hwu
Ipilimumab, a fully human monoclonal antibody against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), is the first immune checkpoint inhibitor approved for the treatment of unresectable melanoma on the basis of its overall survival (OS) benefit. However, ipilimumab is associated with significant immune-related adverse events. We hypothesized that biomarker exploration of pretreatment tumor samples and correlation with clinical outcome would enable patient selection with an increased benefit/risk ratio for ipilimumab therapy...
October 20, 2016: Melanoma Research
Summer E Hanson, Benjamin D Smith, Jun Liu, Geoffrey L Robb, Steven J Kronowitz, Patrick B Garvey
: The most commonly chosen flaps for delayed breast reconstruction after postmastectomy radiation therapy (PMRT) are abdominal-based free flaps (ABFFs) and pedicled latissimus dorsi (LD) musculocutaneous flaps. The short-and long-term advantages and disadvantages of delayed ABFFs versus LD flaps after PMRT remain unclear. We hypothesized that after PMRT, ABFFs would result in fewer postoperative complications and a lower incidence of revision surgery than LD flaps. METHODS: We retrospectively reviewed a prospectively maintained database of consecutive patients who underwent unilateral, delayed breast reconstruction after PMRT using ABFFs or pedicled LD flaps with implants at the MD Anderson Cancer Center between January 1, 2001, and December 31, 2011...
September 2016: Plastic and Reconstructive Surgery. Global Open
N D Fleming, P T Ramirez, P T Soliman, K M Schmeler, G B Chisholm, A M Nick, S N Westin, M Frumovitz
OBJECTIVES: To longitudinally assess quality of life (QOL) in women undergoing radical trachelectomy for early-stage cervical cancer. METHODS: We prospectively enrolled patients with stage IA1-IB1 cervical cancer prior to undergoing radical trachelectomy to complete validated QOL instruments. These instruments included the General Health-Related QOL (SF-12), Functional Assessment of Cancer Therapy-Cervix (FACT-Cx), MD Anderson Symptom Inventory (MDASI), Female Sexual Functioning Index (FSFI), and Satisfaction with Decision scale (SWD)...
October 11, 2016: Gynecologic Oncology
Imran Petkar, Keith Rooney, Justin W G Roe, Joanne M Patterson, David Bernstein, Justine M Tyler, Marie A Emson, James P Morden, Kathrin Mertens, Elizabeth Miles, Matthew Beasley, Tom Roques, Shreerang A Bhide, Kate L Newbold, Kevin J Harrington, Emma Hall, Christopher M Nutting
BACKGROUND: Persistent dysphagia following primary chemoradiation (CRT) for head and neck cancers can have a devastating impact on patients' quality of life. Single arm studies have shown that the dosimetric sparing of critical swallowing structures such as the pharyngeal constrictor muscle and supraglottic larynx can translate to better functional outcomes. However, there are no current randomised studies to confirm the benefits of such swallow sparing strategies. The aim of Dysphagia/Aspiration at risk structures (DARS) trial is to determine whether reducing the dose to the pharyngeal constrictors with dysphagia-optimised intensity- modulated radiotherapy (Do-IMRT) will lead to an improvement in long- term swallowing function without having any detrimental impact on disease-specific survival outcomes...
October 6, 2016: BMC Cancer
Jun Wang, Neda Kalhor, Jianhua Hu, Baocheng Wang, Huili Chu, Bicheng Zhang, Yaping Guan, Yun Wu
BACKGROUND: Neutrophil-to-lymphocyte ratio (NLR) has been shown to be a prognostic indicator in several types of cancer. We aimed to investigate the association between NLR and survival in surgery-treated non-small cell lung cancer (NSCLC) patients. STUDY DESIGN: This large retrospective study included 1,245 patients who underwent initial surgery for stage I-III NSCLC at The University of Texas MD Anderson Cancer Center between December 2002 and November 2010. We analyzed the relationship of NLR with clinicopathological variables, local recurrence-free survival (LRFS), distant recurrence-free survival (DRFS), recurrence-free survival (RFS), overall survival (OS), and disease-specific survival (DSS) in patients with high or low NLR using Kaplan-Meier method...
2016: PloS One
Manojkumar Bupathi, Joud Hajjar, Stacie Bean, Siqing Fu, David Hong, Daniel Karp, Bettzy Stephen, Kenneth Hess, Funda Meric-Bernstam, Aung Naing
Infusion reactions (IRs) to anti-neoplastic agents require prompt recognition and immediate treatment to avert significant complications. We conducted a retrospective review of the medical records of consecutive patients who received anti-neoplastic therapy in the outpatient treatment center of the Department of Investigational Cancer Therapeutics from January 1, 2013 to November 30, 2013. Of the 597 patients who received treatment, 9 (1.5 %) had IRs (all ≤ grade 2). The most common IRs observed on first occurrence were chills (n = 5), itching, rash, and facial flushing (n = 3 each)...
September 29, 2016: Investigational New Drugs
Benjamin Freemyer, Emma Hamilton, Carla L Warneke, Ali M Ali, Cynthia Herzog, Andrea Hayes-Jordan, Mary Austin
PURPOSE: The purpose of this study was to evaluate the impact of hospital specialization on survival in pediatric melanoma. METHODS: We reviewed all patients under 18years old with cutaneous melanoma evaluated at MD Anderson Cancer Center, a National Cancer Institute (NCI)-designated center, from 2000 to 2014. We compared overall survival (OS) and disease-free survival (DFS) between patients who underwent all treatments at MDACC (Group A, n=146) and those who underwent initial surgical treatment at a non-NCI center (Group B, n=58)...
September 17, 2016: Journal of Pediatric Surgery
Uri Rozovski, Srdan Verstovsek, Taghi Manshouri, Vilma Dembitz, Ksenija Bozinovic, Kate Newberry, Ying Zhang, Joseph E Bove, Sherry Pierce, Hagop Kantarjian, Zeev Estrov
In most patients with primary myelofibrosis, one of three mutually exclusive somatic mutations is detected. In approximately 60% of patients, the Janus kinase 2 gene is mutated; in 20%, the calreticulin gene is mutated; and in 5%, the myeloproliferative leukemia virus gene is mutated. Although patients with mutated calreticulin or myeloproliferative leukemia have a favorable outcome and those with none of these mutations have an unfavorable outcome, prognostication based on mutation status is challenging owing to the heterogeneous survival of patients with mutated Janus kinase 2...
September 29, 2016: Haematologica
Jan S Lewin, Leah M Baumgart, Martha P Barrow, Katherine A Hutcheson
Importance: Voice prosthesis (VP) device life is a limiting factor of tracheoesophageal (TE) voice restoration that drives patient satisfaction, health care costs, and overall burden. Historic data suggest that TE VPs have an average device life of generally 3 to 6 months, but these data are typically derived from small samples using only 1 or 2 devices. Objective: To reexamine current device life in a large, contemporary cancer hospital in the United States that uses a wide assortment of VPs...
September 29, 2016: JAMA Otolaryngology—Head & Neck Surgery
Sangeetha N Kalimuthu, Stefano Serra, Neesha Dhani, Sara Hafezi-Bakhtiari, Eva Szentgyorgyi, Rajkumar Vajpeyi, Runjan Chetty
AIM: Several regression grading systems have been proposed for neoadjuvant chemoradiation-treated pancreatic ductal adenocarcinoma (PDAC). This study aimed to examine the utility, reproducibility and level of concordance of three most frequently used grading systems. METHODS: Four gastrointestinal pathologists used the College of American Pathologists (CAP), Evans, MD Anderson Cancer Centre (MDA) regression grading systems to grade 14 selected cases (7-20 slides from each case) of neoadjuvant chemoradiation-treated PDAC...
September 28, 2016: Journal of Clinical Pathology
Alvina A Acquaye, Elizabeth Vera, Mark R Gilbert, Terri S Armstrong
BACKGROUND: Outcomes projects can be a catalyst for determining disease- and treatment-related consequences for patients with rare tumors. The Adult Ependymoma Outcomes (AEO) survey uses self-reported experience to evaluate how this tumor affects patient groups throughout the illness trajectory. METHODS: Patients completed the AEO survey via a Web-based portal. The survey included questions on treatment, tumor recurrence, and current health status; the MD Anderson Symptom Inventory Brain Tumor and Spine Tumor modules; and the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36)...
September 28, 2016: Cancer
H Quon, X Hui, Z Cheng, L C Peng, S P Robertson, J Moore, M R Bowers, B R Page, A P Kiess, J Maclean, M Szczesniak, C G Gourin, I J Cook, T R McNutt
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
Fernando Carceller, Francisco J Bautista, Irene Jiménez, Raquel Hladun-Álvaro, Cécile Giraud, Luca Bergamaschi, Madhumita Dandapani, Isabelle Aerts, François Doz, Didier Frappaz, Michela Casanova, Bruce Morland, Darren R Hargrave, Lynley V Marshall, Gilles Vassal, Andrew D J Pearson, Birgit Geoerger, Lucas Moreno
OBJECTIVES: Dose-finding trials are fundamental to develop novel drugs for children and adolescents with advanced cancer. It is crucial to maximise individual benefit, whilst ensuring adequate assessment of key study end-points. We assessed prognostic factors of survival in paediatric phase I trials, including two predictive scores validated in adult oncology: the Royal Marsden Hospital (RMH) and the MD Anderson Cancer Center (MDACC) scores. METHODS: Data of patients with solid tumours aged <18 years at enrolment in their first dose-finding trial between 2000 and 2014 at eight centres of the Innovative Therapies for Children with Cancer European consortium were collected...
November 2016: European Journal of Cancer
Keith Fournier, Safia Rafeeq, Melissa Taggart, Paul Kanaby, Jing Ning, Hsiang-Chun Chen, Michael Overman, Kanwal Raghav, Cathy Eng, Paul Mansfield, Richard Royal
BACKGROUND: Low-grade appendiceal mucinous neoplasm of uncertain malignant potential are poorly understood lesions characterized by extraluminal mucin or fibrosis with neoplastic cells confined to the appendiceal lumen. The purpose of this study is to investigate the clinical and pathologic parameters of these lesions to optimize our understanding and management of these tumors. METHODS: Subjects with these tumors were identified from the appendiceal tumor databases at the University of Texas MD Anderson Cancer Center...
September 22, 2016: Annals of Surgical Oncology
Erik P Rader, Rolf Turk, Tobias Willer, Daniel Beltrán, Kei-Ichiro Inamori, Taylor A Peterson, Jeffrey Engle, Sally Prouty, Kiichiro Matsumura, Fumiaki Saito, Mary E Anderson, Kevin P Campbell
Dystroglycan (DG) is a highly expressed extracellular matrix receptor that is linked to the cytoskeleton in skeletal muscle. DG is critical for the function of skeletal muscle, and muscle with primary defects in the expression and/or function of DG throughout development has many pathological features and a severe muscular dystrophy phenotype. In addition, reduction in DG at the sarcolemma is a common feature in muscle biopsies from patients with various types of muscular dystrophy. However, the consequence of disrupting DG in mature muscle is not known...
September 27, 2016: Proceedings of the National Academy of Sciences of the United States of America
Qiuling Shi, Tito R Mendoza, Xin Shelley Wang, Charles S Cleeland
OBJECTIVES: Improving, stable, or deteriorating patient functioning is critical to assess in cancer care and in oncology clinical trials. We evaluated the performance of the six-item interference subscale of the MD Anderson Symptom Inventory (MDASI) compared with two commonly used patient-reported measures of functioning as a reference: the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) and the Medical Outcomes Study Short Form 12-item health survey (SF-12)...
November 2016: European Journal of Cancer
Xuemin Gu, Nan Chen, Caimiao Wei, Suyu Liu, Vassiliki A Papadimitrakopoulou, Roy S Herbst, J Jack Lee
We propose a Bayesian two-stage biomarker-based adaptive randomization (AR) design for the development of targeted agents. The design has three main goals: (1) to test the treatment efficacy, (2) to identify prognostic and predictive markers for the targeted agents, and (3) to provide better treatment for patients enrolled in the trial. To treat patients better, both stages are guided by the Bayesian AR based on the individual patient's biomarker profiles. The AR in the first stage is based on a known marker...
June 2016: Statistics in Biosciences
Rhea Li, Hayley Donnella, Phillip Knouse, Margaret Raber, Karla Crawford, Maria C Swartz, Jimin Wu, Diane Liu, Joya Chandra
BACKGROUND: Quality of life in survivors of pediatric acute lymphocytic leukemia (ALL) can be compromised by chronic diseases including increased risk of second cancers, cardiovascular disease, and diabetes. Overweight or obesity further increases these risks. Steroids are a component of chemotherapy for ALL, and weight gain is a common side effect. To impact behaviors associated with weight gain, we conducted a randomized nutrition counseling intervention in ALL patients on treatment...
September 12, 2016: Pediatric Blood & Cancer
Vipulkumar Dadhania, Miao Zhang, Li Zhang, Jolanta Bondaruk, Tadeusz Majewski, Arlene Siefker-Radtke, Charles C Guo, Colin Dinney, David E Cogdell, Shizhen Zhang, Sangkyou Lee, June G Lee, John N Weinstein, Keith Baggerly, David McConkey, Bogdan Czerniak
BACKGROUND: It has been suggested that bladder cancer can be divided into two molecular subtypes referred to as luminal and basal with distinct clinical behaviors and sensitivities to chemotherapy. We aimed to validate these subtypes in several clinical cohorts and identify signature immunohistochemical markers that would permit simple and cost-effective classification of the disease in primary care centers. METHODS: We analyzed genomic expression profiles of bladder cancer in three cohorts of fresh frozen tumor samples: MD Anderson (n=132), Lund (n=308), and The Cancer Genome Atlas (TCGA) (n=408) to validate the expression signatures of luminal and basal subtypes and relate them to clinical follow-up data...
August 25, 2016: EBioMedicine
(no author information available yet)
Gordon Mills, MD, PhD, chair of systems biology at The University of Texas MD Anderson Cancer Center in Houston, discusses a third category of genomic aberrations besides oncogene activation or tumor suppressor inactivation: neomorphs, or mutations that rewire cellular signaling in unexpected ways, with important functional consequences.
October 2016: Cancer Discovery
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"